Effects of two lipid lowering therapies on immune responses in hyperlipidemic subjects

Effects of two lipid lowering therapies on immune responses in hyperlipidemic subjects

Author Moreira, Flavio Tocci Autor UNIFESP Google Scholar
Ramos, Silvia Cristina Autor UNIFESP Google Scholar
Monteiro, Andrea Moreira Google Scholar
Helfenstein, Tatiana Autor UNIFESP Google Scholar
Gidlund, Magnus Google Scholar
Teixeira Damasceno, Nagila Raquel Google Scholar
Figueiredo Neto, Antonio Martins Google Scholar
Izar, Maria Cristina Autor UNIFESP Google Scholar
Helfenstein Fonseca, Francisco Antonio Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Universidade de São Paulo (USP)
Abstract Aims: To compare the effects of two of the most effective lipid-lowering therapies with similar LDL-cholesterol reduction capacity on the innate and adaptive immune responses through the evaluation of autoantibodies anti-oxidized LDL (anti-oxLDL Abs) and electronegative LDL [LDL(-)] levels.Main methods: We performed a prospective, randomized, open label study, with parallel arms and blinded endpoints. One hundred and twelve subjects completed the study protocol and received rosuvastatin 40 mg or ezetimibe/simvastatin 10/40 mg for 12 weeks. Lipids, apolipoproteins, LDL(-), and anti-oxLDL Abs (IgG) were assayed at baseline and end of study.Key findings: Main clinical and laboratory characteristics were comparable at baseline. Lipid modifications were similar in both treatment arms, however, a significant raise in anti-oxLDL Abs levels was observed in subjects treated with rosuvastatin (p = 0.026 vs. baseline), but not in those receiving simvastatin/ezetimibe. (p = 0.233 vs. baseline), thus suggesting modulation of adaptive immunity by a potent statin. Titers of LDL(-) were not modified by the treatments.Significance: Considering atherosclerosis as an immune disease, this study adds new information, showing that under similar LDL-cholesterol reduction, the choice of lipid-lowering therapy can differently modulate adaptive immune responses. (c) 2014 Elsevier Inc. All rights reserved.
Keywords Dyslipidemia
Electronegative low-density lipoprotein
Oxidized LDL
Statins
Ezetimibe
Language English
Sponsor National Institute of Science and Technology on Complex Fluids (INCT-FCx)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Date 2014-03-11
Published in Life Sciences. Oxford: Pergamon-Elsevier B.V., v. 98, n. 2, p. 83-87, 2014.
ISSN 0024-3205 (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 83-87
Origin http://dx.doi.org/10.1016/j.lfs.2014.01.001
Access rights Closed access
Type Article
Web of Science ID WOS:000332443000004
URI http://repositorio.unifesp.br/handle/11600/37549

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account